M701 Bispecific Antibody

M701 · Wuhan YZY Biopharma Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for M701 Bispecific Antibody, covering 2025-07-20 to 2025-07-20. Get the full timeline:

Most recent: Clinical Trial Update: Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody [Phase 2]